BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/17/2023 9:20:32 AM | Browse: 126 | Download: 443
Publication Name World Journal of Psychiatry
Manuscript ID 87700
Country China
Received
2023-08-23 06:42
Peer-Review Started
2023-08-23 06:44
To Make the First Decision
Return for Revision
2023-09-28 10:04
Revised
2023-10-11 09:28
Second Decision
2023-10-24 07:58
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2023-10-27 09:11
Articles in Press
2023-10-27 09:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2023-11-10 03:29
Publish the Manuscript Online
2023-11-17 09:20
ISSN 2220-3206 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Psychiatry
Manuscript Type Observational Study
Article Title Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance
Manuscript Source Unsolicited Manuscript
All Author List Yu-Mei Wei, Xi-Jin Wang, Xiao-Dong Yang, Chuan-Sheng Wang, Li-Li Wang, Xiao-Ying Xu, Gui-Jun Zhao, Bin Li, Dao-Min Zhu, Qi Wu and Yi-Feng Shen
ORCID
Author(s) ORCID Number
Yu-Mei Wei http://orcid.org/0000-0003-0708-0237
Xi-Jin Wang http://orcid.org/0009-0004-0700-0625
Xiao-Dong Yang http://orcid.org/0009-0005-2766-5285
Chuan-Sheng Wang http://orcid.org/0009-0000-1002-2391
Li-Li Wang http://orcid.org/0009-0008-3503-0740
Xiao-Ying Xu http://orcid.org/0009-0007-7527-1015
Gui-Jun Zhao http://orcid.org/0009-0006-0264-9673
Bin Li http://orcid.org/0009-0006-2977-8213
Dao-Min Zhu http://orcid.org/0009-0007-4843-7323
Qi Wu http://orcid.org/0009-0004-5134-9808
Yi-Feng Shen http://orcid.org/0000-0002-3298-6682
Funding Agency and Grant Number
Funding Agency Grant Number
Collaborative Innovation Center Project of Translational Medicine, Shanghai Jiaotong University School of Medicine TM202116PT (2021-2023)
Clinical Research Plan of SHDC SHDC2022CRS032
the Sumitomo Pharmaceuticals (Suzhou) Co., Ltd
Corresponding Author Yi-Feng Shen, MD, PhD, Professor, Shanghai Key Laboratory of Psychotic Disorders, Shanghai Clinical Research Center for Mental Health, Shanghai Jiao Tong University, No. 600 Wanping Nan Road, Shanghai 200030, China, Shanghai 200030, China. shenyifeng@sina.com
Key Words Lurasidone; Safety; Effectiveness; Surveillance; Schizophrenia; Chinese
Core Tip We conducted the first post-marketing surveillance of the actual use of lurasidone in the treatment of patients with schizophrenia in real-world clinical practice since the drug was licensed in mainland China in 2019, and evaluated the safety profile and effectiveness of lurasidone in Chinese population. Here, we report an interim analysis based on 965 patients who received the medication between 2019 and 2022. This study hold significance as it contributes additional safety and effectiveness data on lurasidone beyond what was gathered in pre-marketing trials. Furthermore, it provides valuable reference information for clinical decision-making of schizophrenia treatment.
Publish Date 2023-11-17 09:20
Citation Wei YM, Wang XJ, Yang XD, Wang CS, Wang LL, Xu XY, Zhao GJ, Li B, Zhu DM, Wu Q, Shen YF. Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance. World J Psychiatry 2023; 13(11): 937-948
URL https://www.wjgnet.com/2220-3206/full/v13/i11/937.htm
DOI https://dx.doi.org/10.5498/wjp.v13.i11.937
Full Article (PDF) WJP-13-937-with-cover.pdf
Full Article (Word) WJP-13-937.docx
STROBE Statement 87700-STROBE statement.pdf
Manuscript File 87700_Auto_Edited-JLW.docx
Answering Reviewers 87700-Answering reviewers.pdf
Audio Core Tip 87700-Audio core tip.mp3
Biostatistics Review Certificate 87700-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 87700-Conflict-of-interest statement.pdf
Copyright License Agreement 87700-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 87700-Grant application form(s).pdf
Signed Informed Consent Form(s) or Document(s) 87700-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 87700-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 87700-Language certificate.pdf
Peer-review Report 87700-Peer-review(s).pdf
Scientific Misconduct Check 87700-Bing-Lin C-2.png
Scientific Editor Work List 87700-Scientific editor work list.pdf
CrossCheck Report 87700-CrossCheck.png
CrossCheck Report 87700-CrossCheck report.pdf